May 19, 2021 05:00 PM EDT

#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over

Kyle Blankenship

In a red-hot EGFR-mutated non-small cell lung cancer market, Johnson & Johnson thinks it could have a leader in its bispecific antibody amivantamab. But as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks it over

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

#ASCO21: J&J busts out a small update for its antibody-TKI combo in lung cancer — whetting appetites as FDA thinks it over